Market atlas / Incretins / Liraglutide

Liraglutide (GLP-1 agonist)

repurposedpeptideglp1-receptor-agonismmetabolicweight-loss● body-weight● hba1c

Stage by geography

Same development stage across markets, but Switzerland reached it about 14 years before United Kingdom.

signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUSUKCNJPCHSGILKRIN+1 stages

MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS

What each market approved it for

Market	Stage	Since	Indication / class / form
US	approved	not dated	class GLP-1 Receptor Agonist [EPC]
UK	approved	2024-04-12	indication Adults BIOLIDE injection is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an…
CN	approved	2023-06-30	form Injection, biologic
IN	RCT	2006-05-01	not published
JP	approved	2010-01-20	indication A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to…
CH	approved	2009-12-11	indication Antidiabetic
SG	approved	2010-12-30	form Injection, solution, subcutaneous, prescription only
IL	approved	2021-02-28	indication Adults Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial…
KR	approved	2010-10-06	class Diabetes agents [MFDS 03960]

China registers · NMPA

What each NMPA register actually approved. Reference approval NMPA S20233110. Domestic generics vs imported originator.

6domestic approvals

Forms listed: 1
Product: Liraglutide Injection
Form: injection
Strength: 3ml:18mg (cartridge)
Holder: Hangzhou Zhongmei Huadong Pharmaceutical
Origin: China
Approved: 2023-06-30
Approval no: NMPA S20233110

2imported approvals

approval count only; per-product detail not captured

Biomarker trends

no biomarker readings yet

Studies

The studies on Liraglutide, what they found, in whom and how strongly, are on its evidence page, each linked to its source.

What the trials measure

Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.

Registered primary endpoint	Markets measuring it
Change in HbA1c (Glycosylated Haemoglobin)	CH, IL, IN
Change in Glycosylated Haemoglobin A1c (HbA1c)	IN, KR
Time to Inadequate Glycaemic Control	IN
Change in HbA1c From Randomization to Approximately 16 Weeks	IN
Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Comparative Period	IL
Glucose levels 2 hours after 75 gr OGTT	IL
Change in weight	KR
The incidence of SADRs (Serious Adverse Drug Reactions)	KR
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered…	SG

Connections

Trajectory

2006

MarketIN: rct (clinical trials (highest phase 3))

NCT00318461 · machine-extracted

2009

MarketCH: approved-other (Swissmedic-authorised (Switzerland))

Swissmedic:liraglutid (2009-12-11) · machine-extracted

2010

MarketJP: approved-other (PMDA-approved (Japan))

PMDA:liraglutide (2010-01-20) · machine-extracted

2010

MarketKR: approved-other (MFDS-approved (South Korea))

MFDS:liraglutide (2010-10-06) · machine-extracted

2010

MarketSG: approved-other (HSA-registered (Singapore))

HSA:liraglutide (2010-12-30) · machine-extracted

2013

Relatedshares a mechanism with Semaglutide

NCT01952145 · machine-extracted

2013

ProfileLiraglutide (GLP-1 agonist)

NCT01952145 · machine-extracted

2021

MarketIL: approved-other (Israel MoH-registered)

IsraelMoH:liraglutide (2021-02-28) · machine-extracted

2023

MarketCN: approved-other (NMPA-approved (domestic + imported))

NMPA:NMPA S20233110 · machine-extracted

2024

MarketUK: approved-other (MHRA-authorised (UK), per eMC SmPC)

EMC:liraglutide (product 100249) · machine-extracted

2026

MarketCH: rct (clinical trials (highest phase 3))

NCT02773368 · machine-extracted

2026

MarketIL: rct (clinical trials (highest phase 3))

NCT02787551 · machine-extracted

2026

MarketJP: rct (clinical trials (highest phase 3))

NCT02911948 · machine-extracted

2026

MarketKR: rct (clinical trials (highest phase 3))

NCT01128894 · machine-extracted

2026

MarketSG: rct (clinical trials (highest phase 3))

NCT02654665 · machine-extracted

2026

MarketUS: approved-other (approved, marketed)

NDA022341 · machine-extracted

Get into the weeds: raw observations + provenance

lira_in  2026-06-29  kind=geography_stage  verify=M
   Liraglutide: registered phase 3 trials in India [NCT00318461]
   source NCT00318461  https://clinicaltrials.gov/study/NCT00318461

swissmedic__dev_liraglutide__CH  2026-07-13  kind=geography_stage  verify=M
   Swissmedic-authorised in Switzerland: liraglutidum (Victoza 6 mg/ml, prefilled pen (Triple-Dose)), first authorisation 2009-12-11. [Swissmedic list of authorised medicinal products]
   source Swissmedic:liraglutid (2009-12-11)  https://www.swissmedic.ch/dam/swissmedic/en/dokumente/internetlisten/erweiterte_ham_ind.xlsx.download.xlsx/erweiterte_ham_ind.xlsx

pmda__dev_liraglutide__JP  2026-07-13  kind=geography_stage  verify=M
   PMDA-approved in Japan: Liraglutide (genetical recombination) (Victoza Subcutaneous Injection 18 mg (Novo Nordisk Pharma Ltd.)), first approval 2010-01-20. [PMDA List of Approved Drugs]
   source PMDA:liraglutide (2010-01-20)  https://www.pmda.go.jp/files/000281190.pdf

mfds__dev_liraglutide__KR  2026-07-13  kind=geography_stage  verify=M
   MFDS-approved in South Korea: Liraglutide (Victoza Pen Inj. 6 mg/mL(Liraglutide)), first approval 2010-10-06. [MFDS drug product-approval list]
   source MFDS:liraglutide (2010-10-06)  https://nedrug.mfds.go.kr/pbp/CCBGA01

hsa__dev_liraglutide__SG  2026-07-13  kind=geography_stage  verify=M
   HSA-registered in Singapore: Liraglutide (Victoza® solution for injection in pre-filled pen 6mg/ml), first registration 2010-12-30. [HSA Listing of Registered Therapeutic Products]
   source HSA:liraglutide (2010-12-30)  https://data.gov.sg/datasets/d_767279312753558cbf19d48344577084/view

lira_edge_sema  2026-06-29  kind=edge  verify=M
   both GLP-1 receptor agonists
   source NCT01952145  https://clinicaltrials.gov/study/NCT01952145

lira_facets  2026-06-29  kind=facets  verify=M
   Liraglutide facets
   source NCT01952145  https://clinicaltrials.gov/study/NCT01952145

israelmoh__dev_liraglutide__IL  2026-07-13  kind=geography_stage  verify=M
   Registered in Israel (Israeli Drug Registry): LIRAGLUTIDE 6 MG / 1 ML (SAXENDA), current registration 2021-02-28. [Israel MoH Drug Registry]
   source IsraelMoH:liraglutide (2021-02-28)  https://israeldrugs.health.gov.il/

lira_cn  2026-06-29  kind=geography_stage  verify=M
   NMPA-approved in China (liraglutide): 6 domestic approval(s) (e.g. Liraglutide Injection, 3ml:18mg (cartridge) , Hangzhou Zhongmei Huadong Pharmaceutical, China); 2 imported approval(s). Reference NMPA S20233110.
   source NMPA:NMPA S20233110  https://www.nmpa.gov.cn/datasearch/home-index.html

lira_uk  2026-07-14  kind=geography_stage  verify=M
   UK marketing authorisation (MHRA), per the eMC SmPC: BIOLIDE 6 mg/ml solution for injection in pre-filled pen [active substance: liraglutide], first authorised 2024-04-12. [electronic Medicines Compendium, medicines.org.uk]
   source EMC:liraglutide (product 100249)  https://www.medicines.org.uk/emc/product/100249/smpc

ctsearch__CH__dev_liraglutide  2026-07-10  kind=geography_stage  verify=M
   liraglutide: 10 registered trial(s) in CH, highest phase 3 [NCT02773368]
   source NCT02773368  https://clinicaltrials.gov/study/NCT02773368

ctsearch__IL__dev_liraglutide  2026-07-10  kind=geography_stage  verify=M
   liraglutide: 23 registered trial(s) in IL, highest phase 3 [NCT02787551]
   source NCT02787551  https://clinicaltrials.gov/study/NCT02787551

ctsearch__JP__dev_liraglutide  2026-07-10  kind=geography_stage  verify=M
   liraglutide: 19 registered trial(s) in JP, highest phase 3 [NCT02911948]
   source NCT02911948  https://clinicaltrials.gov/study/NCT02911948

ctsearch__KR__dev_liraglutide  2026-07-10  kind=geography_stage  verify=M
   liraglutide: 8 registered trial(s) in KR, highest phase 3 [NCT01128894]
   source NCT01128894  https://clinicaltrials.gov/study/NCT01128894

ctsearch__SG__dev_liraglutide  2026-07-10  kind=geography_stage  verify=M
   liraglutide: 4 registered trial(s) in SG, highest phase 3 [NCT02654665]
   source NCT02654665  https://clinicaltrials.gov/study/NCT02654665

openfda__NDA022341__US  2026-07-13  kind=geography_stage  verify=M
   FDA-approved in the US (LIRAGLUTIDE); approved, marketed [NDA022341]
   source NDA022341  https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=NDA022341